Post Pandemic: How a new era of supplier-vender collaboration is transforming Biopharma

by Carole Inglevert | October 27, 2023

Closeup shot of two unrecognisable scientists shaking hands in a lab

The biopharma industry finds itself at a crossroads in 2023. COVID-19 showed the old approaches cannot comfortably scope with disruption, but the industry is yet to settle on a new model and innovative ideas on how to prepare. 2023 is the year to sit down and collectively decide on how to move forward.

Industry collaboration has never been more important. From building more resilient supply chains to unlocking the potential of novel modalities such as adeno-associated virus (AAV), lentivirus gene therapies, mRNA therapies and vaccines: vendors and suppliers have entered a new era.

In many cases, digitalization, automation and artificial intelligence will play a role. And while regulators are still clarifying the requirements for activities such as purification for some modalities, customers and suppliers, faced with the challenges, are collaborating for mutual benefit.

Learn more and read now!
[molongui_author_box]

Related Posts

Starting your journey into manufacturing – choosing a cell line development provider

One of the biggest decisions which any company developing biological medicines makes is to move forward to the manufacture of their product. …

Covid-19 Impact on Bioprocessing: PART 1 Accelerating Trends

The views and opinions expressed in this blog / article are those of the authors and do not…

Covid-19 Impact on Bioprocessing: PART 2 Fears to Be Addressed due to Covid-19

The views and opinions expressed in this blog / article are those of the authors and do not…

Covid-19 Impact on Bioprocessing: PART 3 Long-term Changes Resulting from the Pandemic

The views and opinions expressed in this blog / article are those of the authors and do not…

Scroll to Top